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BACKGROUND/AIM: Desmopressin (dDAVP) is a synthetic peptide analog of 
vasopressin with antidiuretic and hemostatic properties. Recent experimental evidence 
suggested that dDAVP can inhibit metastasis formation by agonist action on V2 
vasopressin receptors present in both tumor and endothelial cells. We have examined 
the kinetics of dDAVP effect during metastatic colonization and its potential association 
with hemostasis. 
MATERIALS AND METHODS: The experimental metastasis assay was performed by 
injecting F3II mammary carcinoma cells into the lateral tail vein of syngeneic female 
BALB/c mice. 
RESULTS: Clinically relevant doses of dDAVP (0.3 to 2 µg/kg, i.v.) produced a dose-
dependent inhibition in the formation of lung nodules when administered during the 
first 24 hours after F3II tumor cell injection. The hemostatic agent tranexamic acid (10 
mg/kg, i.v.) had not effects on metastasis formation in the same experimental 
conditions, and the anticoagulant enoxaparin (1 mg/kg, s.c.) did not modify the 
antimetastatic action of dDAVP. In vitro, dDAVP had a strong inhibitory effect on F3II 
cell colony formation. 
CONCLUSION: dDAVP interferes with early metastatic disease, and direct association 




Desmopressin (dDAVP, 1-deamino-8-D-arginine vasopressin), a synthetic peptide 
analog of vasopressin, was initially described in the late 1960s (1). DDAVP is a 
selective agonist for the V2 vasopressin membrane receptor (V2r), mediating the well-
known antidiuretic action of the compound, as well as a safe hemostatic effect 
associated with release of von Willebrand factor (vWF), coagulation factor VIII and 
tissue-type plasminogen activator from microvascular endothelia (2). Interestingly, V2r 
expression was detected in several tumor variants (3), and selective agonist effect on 
V2r displayed by dDAVP could induce growth inhibition of human breast cancer cells 
(4, 5). 
Previously, we reported for the first time that dDAVP was capable of inhibiting 
lung colonization by blood-borne breast cancer cells in an aggressive experimental 
mouse model (6, 7). Furthermore, perioperative administration of dDAVP significantly 
prolonged survival in dogs with locally advanced mammary cancer (8, 9). The aim of 
the present work was to examine the kinetics of dDAVP effect during metastatic lung 
colonization by F3II mammary carcinoma cells, and its potential association with 
hemostasis. 
 
Materials and Methods 
 
Tumor cells and culture conditions. The F3II cell line is a highly aggressive variant 
derived from a clone of a spontaneous BALB/c mouse mammary tumor, which 
expresses the V2r on the cell surface (5). F3II cells were maintained in monolayer 
culture in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Grand Island, NY, 
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USA) supplemented with 5% fetal bovine serum (FBS), 2 mM glutamine, and 80 µg/ml 
gentamycin. For harvesting, tumor cells were trypsinized using standard procedures.
 
 
Animals. Syngeneic, pathogen-free BALB/c mice were purchased from the School of 
Veterinary Sciences-UNLP (La Plata, Argentina), and kept at our animal house facility 
according to an institutionally approved protocol. Food and water were provided ad 
libitum and general health status of the animals was monitored daily. Adult female mice 
with a weight of 20-25 g were used. 
 
Experimental metastasis assay. F3II cells at a concentration of 2 x 10
5
 viable cells/0.3 
ml DMEM/mouse were injected into the lateral tail vein of unanesthetized mice. After 3 
weeks, animals were sacrificed by cervical dislocation and necropsied. Lungs were 
removed, fixed in Bouin’s solution, and the number of surface lung nodules was 
determined under a dissecting microscope. Selected organs were further processed for 
paraffin embedding and sectioning for histopathological anaylsis. 
 
Administration of dDAVP. Groups of at least 6 animals received dDAVP from Ferring 
Pharmaceuticals (Malmö, Sweden) by the intravenous route in saline solution. The 
compound was administered at the dosage of 0.3–2 µg/kg of body weight. These doses 
are clinically relevant, with proven hemostatic effects and safety in humans (2). To 
investigate the kinetics of dDAVP effect during metastatic lung colonization, treatment 
was given at time zero, 24 hours, 48 hours or 7 days after tumor cell inoculation. 
Controls received only the saline vehicle. 
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Administration of tranexamic acid and enoxaparin. The hemostatic agent tranexamic 
acid (Ariston, Buenos Aires, Argentina) was administered intravenously at a dose of 10 
mg/kg (10) at time zero and/or 24 hours after tumor cell inoculation. The anticoagulant 
enoxaparin (Sanofi Winthrop, Le Trait, France) was given by daily subcutaneous 
injection at a dose of 1 mg/kg (11) for 7 days, starting at the moment of tumor cell 
inoculation. 
 
In vitro studies. Cytostatic effects of dDAVP were studied at low cell density by colony 
formation assay, as described (5). F3II cells were plated at 6 × 10
2
 cells/well in 24-well 
plates and grown for 7 days in complete medium with or without the compound. 
Cultures were then stained with crystal violet and the concentration producing 50% 
inhibition (IC50) was determined by plotting the percentage of cell colonies versus 
dDAVP concentration. Additionally, effects on slowly-growing, subconfluent F3II 
cultures were assayed. 
 
Statistical analysis. Differences were evaluated with the GraphPad Prism 4.0 software 




We first analyzed the kinetics of dDAVP effect during lung colonization by metastatic 
F3II mammary carcinoma cells. As shown in Figure 1, dDAVP reduced about 50-60% 
the formation of lung nodules when administered at time zero or 24 hours after tumor 
cell inoculation, while later dDAVP administration had no effect. Representative 
sections of lungs from control and treated animals are depicted in Figure 2. Multiple 
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subpleural and intrapulmonary nodules were visualized in controls. In contrast, lungs 
from animals receiving early dDAVP treatment showed a few peripheral nodules. We 
have also examined dose dependency for the antimetastatic effect. Following the data 
from the kinetics experiment, mice received two dDAVP intravenous administrations, 
the first coinjected at the time of tumor cell inoculation and the second 24 hours later. 
We observed a clear dose-dependent effect on metastasis formation, showing an 
inhibition of 70% in the higher dDAVP dose of 2 µg/kg (Table I). As expected, similar 
doses administered by the subcutaneous route were not effective (data not shown). 
In order to explore the potential role of hemostatic mechanisms in early 
metastasis formation as well as in the antimetastatic activity of dDAVP, we evaluated 
hemostatic and anticoagulant drugs. Under the same experimental conditions of 
effective dDAVP treatment, the hemostatic agent tranexamic acid had not effects on the 
formation of lung metastasis by F3II cells when administered at time zero and 24 hours 
after tumor cell injection (Figure 3A). Similarly, daily treatment with the anticoagulant 
enoxaparin for 7 days beginning the day of tumor cell injection did not modify the 
antimetastatic action of dDAVP (Figure 3B). 
 As illustrated in Figure 4A, dDAVP had a strong cytostatic effect on in vitro 
colony formation, with an IC50 value of about 0.7 µM against F3II cells, confirming 
previous results with murine and human breast cancer cells (5, 12). On the other hand, 
slowly-growing, subconfluent F3II cultures were not significantly affected by 





The synthetic peptide dDAVP is a selective agonist of V2r present on both endothelial 
and breast cancer cells. Recent evidence indicated that dDAVP promotes tumor-
mediated production of angiostatin (5) and also activates endothelial release of vWF, 
which may affect survival of micrometastatic cells (13). Previous experimental data 
showed that dDAVP is able to inhibit development of metastasis in the aggressive F3II 
mouse mammary cancer model. Here, we demonstrated that dDAVP is effective when 
treatment is applied during the early metastatic events. As expected, control animales 
showed multiple subpleural and intrapulmonary metastatic nodules, while animals 
receiving dDAVP displayed only a few peripheral nodules. On the other hand, dDAVP 
showed a marked dose-dependency in inhibition of metastasis, with highest effects at 
clinical relevant doses of 1-2 µg/kg. 
The systemic release of hemostatic and profibrinolytic factors induced by 
dDAVP could act modulating biological mechanisms of metastasis development. It is 
well known that dDAVP stimulates endothelial cells to release large multimeric forms 
of vWF, provoking a rapid increase of this factor in the circulation (14). VWF has been 
classically described as a hemostatic effector molecule. However, recent studies have 
related this protein with a more complex role since it has been implicated as a regulator 
of angiogenesis, tumor metastasis and also as inductor of apoptosis in cancer cells (15). 
As demonstrated by Terraube et al. (13) vWF could play a protective role against tumor 
cell dissemination in vivo inducing the early death of metastatic cells in the 
microvasculature of the target organ by limiting adherence tumor cell-endothelial cell. 
Moreover, vWF induced apoptosis of highly aggressive carcinoma cells mainly in lung 
blood vessels (16). Inactivation of proapoptotic vWF by ADAM 28 (a disintegrin and 
metalloproteinase 28) improved survival of cancer cells with high level expression of 
ADAM28 at the metastatic site. 
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The antimetastatic effect displayed by dDAVP could not be reproduced by other 
hemostatic agent like tranexamic acid neither was affected by concomitant treatment of 
the anticoagulant enoxaparin. Tranexamic acid is a potent competitive inhibitor of 
plasminogen activation and, at higher concentrations, a non-competitive inhibitor of 
plasmin (17). It has been used for years in the management of peri- and postoperative 
bleeding and blood disorders. Particularly, tranexamic acid administration is a safe 
practice in surgical resection of tumor in cancer patients (18). Enoxaparin is a powerful 
anticoagulant that interferes with the transformation of fibrinogen into fibrin preventing 
production of fibrin clot, the last step in the coagulation cascade. Thus, the mechanism 
of action of dDAVP would not be directly related with coagulation effectors that are at 
the end of the cascade. 
Surgery for malignant disease carries a risk of deep vein thrombosis and 
pulmonary embolization, particularly in pancreatic cancer. Interestingly, enoxaparin is 
safe and effective preventing venous thromboembolism in patients undergoing major 
elective surgery for malignancy (19). In this regard, combination of perioperative 
dDAVP and enoxaparin may result in greater beneficial effects. 
We have also explored the antiproliferative effects of dDAVP on low density 
F3II cultured cells. In this condition, dDAVP displayed a strong effect on the ability of 
F3II cells to form colonies. The cytostatic mechanism of dDAVP was not associated 
with direct cytotoxicity since slowly-growing F3II cultures were not affected by high 
concentrations of dDAVP. 
Our findings suggested that dDAVP effect would not depend of a hemostatic 
direct action but other mechanisms could be playing could be playing a role in the 
antitumor final effect.  
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The specific interaction of dDAVP with V2r triggers antiproliferative mechanisms 
activating adenylate cyclase followed by intracellular cAMP elevation (20). Besides, 
dDAVP stimulates tumor-mediated production of angiostatin, a strong angiogenesis 
inhibitor (5). The compound induces secretion of urokinase-type plasminogen activator, 
favoring angiostatin generation by the proteolityc cleavage of plasminogen (21). The 
endothelial release of vWF by dDAVP as well, would be acting as a cooperative 
mechanism that helps to obstruct metastatic spread. 
The biological effects of dDAVP administration on both endothelial and V2r-
expressing cancer cells are complex, and further investigations are required. Although a 
hemostatic mediator such as vWF may be involved, among other factors, the compound 
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Table I – Dose-dependent effects of dDAVP on lung colonization by F3II mammary 
carcinoma cells. Mice were injected with 2 x 10
5
 F3II cells into the lateral tail vein, and 




 Percent reduction of lung nodules
B
 
dDAVP 0.3 µg/kg 
dDAVP 1 µg/kg 






Two dDAVP administrations were performed for each dose level, the first at time zero 
and the second 24 hours after tumor cell injection. 
B
Lung nodules were counted under a dissecting microscope, and percent reduction of 
median values with respect to controls was calculated. 




Figure 1. Kinetics of dDAVP on lung colonization by F3II cells. 2 x 10
5
 F3II cells per 
mouse were injected into the lateral tail vein of BALB/c mice. A dose of 1 µg/kg of 
dDAVP was administrated at time zero, 24 hours, 48 hours or 7 days after tumor cell 
inoculation. Controls received saline vehicle. Data points represent individual mice and 
horizontal lines indicate the median values from two independent experiments. *p<0.05 
versus control, Kruskal-Wallis plus Dunn´s test. (at least 6 animals per group were 
used). 
 
Figure 2. Representative microphotographs of lungs from control mice receiving saline 
solution, and mice treated with dDAVP (1 µg/kg) at time zero (dDAVP 0h) or 7 days 
(dDAVP 7d) after inoculation of F3II mammary carcinoma cells. Hematoxylin and 
eosin, original magnification X40. 
 
Figure 3. Effect of treatment of 10 mg/kg i.v of tranexamic acid (A) and 1 mg/kg/day 
s.c. of the anticoagulant agent enoxaparin (B) on metastatic dissemination. Results are 
expressed as mean ± standard error from two independent experiments. **p<0.05 versus 
control, Kruskal-Wallis plus Dunn´s test. 
 
Figure 4. Antiproliferative effect of dDAVP on F3II cells. (A) Representative 
microphotographs of the effect of seven-day treatment of dDAVP on the colony 
formation assay at low density. Quantitative analysis (right) of number of colonies per 
quadrant are also shown. Values represent mean ± standard error. Results are 
representative of three independent experiments. ***p< 0.001, t test. (B) Representative 
microphotographs subconfluent of F3II cultures treated or not with 1 µM of dDAVP. 
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No direct effect was observed with 24 hours incubation of dDAVP. (Original 
magnification X100). 
 
 
